UBX - Unity Biotechnology Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

3.839M

Cash

69.09M

Avg Qtr Burn

-10.91M

Short % of Float

4.72%

Insider Ownership

1.43%

Institutional Own.

29.13%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Foselutoclax (UBX1325) (Bcl-xL inhibitor) Details Diabetic macular edema	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Foselutoclax (UBX1325) (Bcl-xL inhibitor) Details Diabetic retinopathy , Diabetic macular edema, Age-related macular degeneration	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.